Loading…
Entero Healthcare Solutions (ENTERO)₹2,115+4.42%Pharmacy Retail
In the Jun 2026 quarter (consolidated), Entero Healthcare Solutions reported sales of ₹1,940 Cr, up 38.1% from Jun 2025, and net profit of ₹52.01 Cr, up 73.5% year on year. For the year to Mar 2026, sales were ₹6,595 Cr and net profit ₹146 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 996 | 993 | 1,034 | 1,098 | 1,302 | 1,359 | 1,341 | 1,405 | 1,572 | 1,709 | 1,911 | 1,940 |
| Expenses | 968 | 964 | 1,005 | 1,066 | 1,257 | 1,308 | 1,290 | 1,353 | 1,509 | 1,640 | 1,824 | 1,842 |
| Operating Profit | 28.90 | 28.89 | 28.91 | 29.88 | 41.84 | 49.87 | 48.84 | 49.81 | 61.79 | 67.80 | 85.75 | 96.64 |
| OPM % | 2.9% | 2.9% | 2.8% | 2.8% | 3.3% | 3.7% | 3.6% | 3.6% | 4.0% | 4.0% | 4.5% | 5.0% |
| Other Income | 1.99 | 1.99 | 8.98 | 12.96 | 10.96 | 7.97 | 6.98 | 5.98 | 4.99 | −3.99 | 3.99 | 2.99 |
| Interest | 17.93 | 15.95 | 16.95 | 9.97 | 10.96 | 9.97 | 9.97 | 10.97 | 11.97 | 13.96 | 16.95 | 20.94 |
| Depreciation | 5.98 | 5.99 | 6.98 | 6.98 | 6.98 | 7.98 | 7.98 | 8.97 | 9.97 | 9.97 | 14.96 | 11.97 |
| Profit before tax | 7.02 | 8.02 | 14.04 | 27.10 | 35.09 | 39.09 | 37.10 | 36.10 | 45.14 | 40.11 | 58.22 | 67.16 |
| Tax % | 23.1% | 16.0% | −56.0% | 25.1% | 25.0% | 25.0% | 16.1% | 17.1% | 18.0% | 16.1% | 22.1% | 22.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −4.01 | 0.00 | 0.00 |
| Net Profit | 4.99 | 6.99 | 20.99 | 20.99 | 26.01 | 28.99 | 31.01 | 29.98 | 36.99 | 33.98 | 44.99 | 52.01 |
| EPS (Rs) | 3.18 | 4.21 | 4.81 | 4.61 | 5.42 | 5.84 | 5.89 | 6.38 | 7.25 | 6.34 | 6.43 | 8.76 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,350 | 1,773 | 2,522 | 3,301 | 3,921 | 5,102 | 6,595 | 7,132 |
| Expenses | 1,325 | 1,757 | 2,498 | 3,233 | 3,810 | 4,926 | 6,325 | 6,815 |
| Operating Profit | 22.94 | 14.95 | 23.93 | 63.81 | 112 | 171 | 265 | 312 |
| OPM % | 1.7% | 0.8% | 1.0% | 1.9% | 2.9% | 3.4% | 4.0% | 4.4% |
| Other Income | 4.99 | 10.97 | 3.99 | 5.99 | 13.96 | 38.89 | 10.97 | 7.98 |
| Interest | 12.95 | 19.94 | 28.91 | 48.85 | 65.79 | 41.87 | 53.84 | 63.82 |
| Depreciation | 11.96 | 15.97 | 19.93 | 23.93 | 24.94 | 30.92 | 42.89 | 46.87 |
| Profit before tax | 4.01 | −11.04 | −20.06 | −4.01 | 36.11 | 139 | 180 | 211 |
| Tax % | 67.1% | 42.1% | 49.1% | 201.1% | −12.0% | 23.1% | 19.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −4.01 | −4.01 |
| Net Profit | 1.01 | −14.99 | −28.99 | −11.01 | 39.99 | 107 | 146 | 168 |
| EPS (Rs) | 93.75 | −1,549.16 | −77.69 | −28.08 | 8.98 | 21.76 | 26.41 | 28.78 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.11 | 0.11 | 4.01 | 4.01 | 42.98 | 44.07 | 44.06 |
| Reserves | −15.99 | −31.96 | −61.88 | −72.90 | 1,592 | 1,678 | 1,644 |
| Borrowings | 601 | 718 | 970 | 1,097 | 337 | 383 | 674 |
| Other Liabilities | 162 | 148 | 211 | 276 | 367 | 590 | 1,228 |
| Total Liabilities | 747 | 834 | 1,122 | 1,305 | 2,338 | 2,695 | 3,590 |
| Fixed Assets | 186 | 188 | 261 | 267 | 288 | 557 | 956 |
| CWIP | 2.01 | 2.01 | 1.01 | 0.00 | 0.00 | 0.00 | 2.01 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.04 | 130 |
| Other Assets | 558 | 644 | 861 | 1,038 | 2,050 | 2,079 | 2,502 |
| Inventories | 195 | 244 | 310 | 342 | 421 | 660 | 843 |
| Trade receivables | 231 | 242 | 374 | 513 | 613 | 827 | 1,208 |
| Cash & equivalents | 70.72 | 82.73 | 105 | 107 | 890 | 259 | 161 |
| Total Assets | 747 | 834 | 1,122 | 1,305 | 2,338 | 2,695 | 3,590 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | −37.07 | −69.18 | −35.09 | −45.08 | −37.10 | −77.10 | 96.22 |
| Cash from investing activity | −203 | −31.07 | −162 | −49.09 | −705 | 232 | −303 |
| Cash from financing activity | 217 | 88.72 | 210 | 72.74 | 860 | −73.82 | 124 |
| Net cash flow | −22.95 | −10.97 | 13.96 | −20.93 | 122 | 81.72 | −81.83 |
| Capex | 44.98 | 9.99 | 10.01 | 6.01 | 5.01 | 11.01 | 68.04 |
| Free cash flow | −81.01 | −78.01 | −44.98 | −50.99 | −40.99 | −86.99 | 28.97 |
| CFO / OP % | −134.1% | −430.1% | −100.1% | −51.1% | −21.1% | −23.1% | 55.9% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 64 | 51 | 55 | 58 | 58 | 60 | 68 |
| Inventory days | 57 | 54 | 49 | 41 | 43 | 52 | 52 |
| Days payable | 31 | 21 | 21 | 24 | 23 | 30 | 44 |
| Cash conversion cycle | 88 | 82 | 81 | 73 | 77 | 80 | 74 |
| Working capital days | 58 | 55 | 42 | 33 | 49 | 66 | 36 |
| ROCE % | — | 1.0% | 1.0% | 5.0% | 7.0% | 9.0% | 10.0% |
For the Jun 2026 quarter, Entero Healthcare Solutions reported sales of ₹1,940 Cr, up 38.1% year on year and net profit of ₹52.01 Cr, up 73.5% year on year. The operating margin was 5.0%.
Entero Healthcare Solutions' sales for the year to Mar 2026 were ₹6,595 Cr; over the last twelve months they were ₹7,132 Cr.
Net profit for the year to Mar 2026 was ₹146 Cr, and ₹168 Cr over the last twelve months. Earnings per share over the same trailing period were ₹28.78.
Entero Healthcare Solutions reported borrowings of ₹674 Cr at Mar 2026, against cash and equivalents of ₹161 Cr.
Cash from operations was ₹96.22 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹28.97 Cr.